X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5489) 5489
animals (3983) 3983
poly polymerases - metabolism (3740) 3740
apoptosis (3515) 3515
poly polymerase (3150) 3150
apoptosis - drug effects (2699) 2699
cell line, tumor (2061) 2061
mice (2041) 2041
oncology (2013) 2013
poly polymerase inhibitors (1960) 1960
cancer (1663) 1663
biochemistry & molecular biology (1581) 1581
female (1425) 1425
enzyme inhibitors - pharmacology (1423) 1423
male (1406) 1406
cell biology (1387) 1387
activation (1347) 1347
antineoplastic agents - pharmacology (1274) 1274
pharmacology & pharmacy (1227) 1227
proteins (1162) 1162
rats (1122) 1122
caspases - metabolism (1112) 1112
poly polymerase-1 (1083) 1083
dna damage (1080) 1080
cell survival - drug effects (1075) 1075
expression (957) 957
cell proliferation - drug effects (922) 922
oxidative stress (913) 913
inhibition (909) 909
dna repair (847) 847
dose-response relationship, drug (835) 835
caspase (782) 782
caspase 3 - metabolism (780) 780
cell death (775) 775
cell line (771) 771
cells, cultured (763) 763
death (750) 750
phosphorylation (750) 750
benzamides - pharmacology (708) 708
cell cycle (706) 706
blotting, western (705) 705
signal transduction (695) 695
chemotherapy (680) 680
signal transduction - drug effects (662) 662
caspase 3 (658) 658
research (657) 657
deoxyribonucleic acid--dna (648) 648
tumors (646) 646
cells (644) 644
ribose (640) 640
caspase-3 (624) 624
multidisciplinary sciences (618) 618
tumor cells, cultured (610) 610
research article (609) 609
kinases (607) 607
poly polymerase inhibitors - pharmacology (593) 593
cytotoxicity (590) 590
poly polymerases - genetics (589) 589
analysis (583) 583
breast cancer (580) 580
inhibitors (580) 580
gene expression (579) 579
dna (578) 578
mitochondria (567) 567
in-vitro (541) 541
reactive oxygen species - metabolism (535) 535
enzyme activation (528) 528
enzyme activation - drug effects (524) 524
medicine (524) 524
dna-damage (517) 517
proto-oncogene proteins c-bcl-2 - metabolism (513) 513
flow cytometry (510) 510
parp (507) 507
time factors (507) 507
cell-death (488) 488
apoptosis - physiology (486) 486
mutation (484) 484
neurosciences (461) 461
monosaccharides (460) 460
adenosine diphosphate (456) 456
sugars (454) 454
chemistry, medicinal (450) 450
mitochondria - metabolism (445) 445
repair (441) 441
cancer therapies (436) 436
biology (429) 429
science (429) 429
health aspects (422) 422
drug synergism (420) 420
care and treatment (418) 418
homologous recombination (413) 413
dna fragmentation (406) 406
enzymes (406) 406
cell proliferation (401) 401
poly (401) 401
toxicology (401) 401
mitochondria - drug effects (399) 399
nf-kappa-b (393) 393
xenograft model antitumor assays (393) 393
caspase inhibitors (392) 392
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8255) 8255
Japanese (48) 48
Chinese (42) 42
French (9) 9
Russian (9) 9
German (6) 6
Hungarian (4) 4
Ukrainian (3) 3
Korean (2) 2
Norwegian (2) 2
Polish (2) 2
Italian (1) 1
Portuguese (1) 1
Spanish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of pharmacology and experimental therapeutics, ISSN 1521-0103, 2015, Volume 353, Issue 3, pp. 446 - 457
Journal Article
Science (American Association for the Advancement of Science), ISSN 1095-9203, 2018, Volume 362, Issue 6414, pp. eaat8407 - 557
.... PARP inhibitors or genetic deletion of PARP-1 prevented pathologic α-syn toxicity. In a feed-forward loop, PAR converted pathologic α... 
STRAINS | MECHANISMS | PROTEIN | MULTIDISCIPLINARY SCIENCES | AGGREGATION | CELL-DEATH | Recombinant Proteins - metabolism | Parkinson Disease - pathology | Dopaminergic Neurons - pathology | Mice, Inbred C57BL | Poly (ADP-Ribose) Polymerase-1 - metabolism | Recombinant Proteins - genetics | Gene Knockout Techniques | Poly (ADP-Ribose) Polymerase-1 - antagonists & inhibitors | Mice, Knockout | Brain - metabolism | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Poly Adenosine Diphosphate Ribose - metabolism | Animals | Dopaminergic Neurons - metabolism | Cell Death | Brain - pathology | Benzimidazoles - pharmacology | Mice | Parkinson Disease - metabolism | alpha-Synuclein - genetics | Enzyme Activation | Nitric Oxide - metabolism | alpha-Synuclein - metabolism | Poly (ADP-Ribose) Polymerase-1 - genetics | Therapy | Parkinson's disease | Pathogenesis | Disorders | Cognitive ability | Nervous system | Cerebrospinal fluid | Rigidity | Mental depression | Proteins | Fibrillogenesis | Cell activation | Neurodegeneration | Autonomic nervous system | Neostriatum | Biocompatibility | Anxiety | Inhibition | Toxic diseases | Constipation | Movement disorders | Deoxyribonucleic acid--DNA | Neurodegenerative diseases | Mortality | Adenosine diphosphate | Pathology | Cell injury | Molecular modelling | Inhibitors | Nitric oxide | Biomarkers | Toxicity | DNA damage | Activation | Accumulation | Neurotoxicity | Clonal deletion | Feedforward | Phenotypes | Adenosine | Dopamine | Neurons | Poly(ADP-ribose) polymerase | Caspase | Axons | Sleep | Cell death | In vivo methods and tests | Apoptosis | Index Medicus
Journal Article
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2017, Volume 35, Issue 19, pp. 2193 - 2202
Purpose Data suggest that DNA damage by poly (ADP-ribose) polymerase inhibition and/or reduced vascular endothelial growth factor signaling by vascular... 
SENSITIVE OVARIAN-CANCER | MULTICENTER | ANTI-PD-1 | ONCOLOGY | ANTITUMOR-ACTIVITY | NIVOLUMAB | Piperazines - administration & dosage | Vascular Endothelial Growth Factor Receptor-1 - antagonists & inhibitors | Phthalazines - pharmacokinetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Quinazolines - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Genital Neoplasms, Female - drug therapy | Adult | Female | Quinazolines - administration & dosage | Piperazines - pharmacokinetics | Phthalazines - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Genital Neoplasms, Female - immunology | B7-H1 Antigen - immunology | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Genital Neoplasms, Female - metabolism | Protein Kinase Inhibitors - administration & dosage | B7-H1 Antigen - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | B7-H1 Antigen - biosynthesis | Quinazolines - adverse effects | Aged | Genital Neoplasms, Female - pathology | Phthalazines - adverse effects | Lymphocytes, Tumor-Infiltrating - immunology | Index Medicus | Phase I and Clinical Pharmacology | Combined Modality | Breast Cancer | ORIGINAL REPORTS
Journal Article
Journal Article
Cancer science, ISSN 1347-9032, 2019, Volume 110, Issue 3, pp. 1064 - 1075
Poly(ADP‐ribose) polymerase (PARP) enzymes play an important role in repairing DNA damage and maintaining genomic stability... 
toxicity | pharmacokinetics | poly(ADP‐ribose) polymerase | fluzoparib | antitumor activity | poly(ADP-ribose) polymerase | DOWN-REGULATION | OVARIAN-CANCER | COMBINATION | TUMORS | MAINTENANCE THERAPY | OLAPARIB | ONCOLOGY | DOUBLE-BLIND | AGENTS | HOMOLOGOUS RECOMBINATION | PARP INHIBITORS | DNA Repair - drug effects | Apoptosis - drug effects | Humans | Rats | Clinical Trials as Topic | Xenograft Model Antitumor Assays - methods | Piperazines - pharmacology | Rats, Sprague-Dawley | Phthalazines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Poly(ADP-ribose) Polymerases - metabolism | Animals | DNA Breaks, Double-Stranded - drug effects | Mice, Nude | Cell Line, Tumor | Female | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Clinical trials | DNA damage | Sugars | Monosaccharides | Cell proliferation | Homologous recombination | Cytotoxicity | Metastasis | Kinases | Cancer therapies | DNA repair | Stomach cancer | Defects | Ovarian cancer | Homologous recombination repair | Enzymatic activity | Ribose | Paclitaxel | Xenografts | Drug dosages | Deoxyribonucleic acid--DNA | Enzymes | Poly(ADP-ribose) polymerase | Breast cancer | FDA approval | Poly(ADP-ribose) Polymerase 1 | Antitumor activity | Hypoxia | Software | Apoptosis | Pharmaceuticals | Index Medicus | Original
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 03/2007, Volume 13, Issue 5, pp. 1383 - 1388
Poly(ADP-ribose) polymerase (PARP) is a nuclear enzyme that signals the presence of DNA damage by catalyzing the addition of ADP-ribose units to DNA, histones, and various DNA repair enzymes and by facilitating DNA repair... 
Clinical Repair | DNA Repair | PARP | POLY(ADP-RIBOSE) POLYMERASE | REPAIR | RADIOSENSITIZATION | ONCOLOGY | DNA-DAMAGE | DEPENDENT PROTEIN-KINASE | DOUBLE-STRAND BREAKS | POTENT INHIBITORS | PARP-1 | CELL-DEATH | TEMOZOLOMIDE | Poly(ADP-ribose) Polymerases - drug effects | Poly(ADP-ribose) Polymerases - metabolism | Animals | Humans | Enzyme Inhibitors - pharmacology | Antineoplastic Agents - pharmacology | Clinical Trials as Topic
Journal Article
Current protein & peptide science, ISSN 1389-2037, 11/2016, Volume 17, Issue 7, pp. 668 - 682
Journal Article
Cancer science, ISSN 1347-9032, 2018, Volume 109, Issue 11, pp. 3383 - 3392
...‐directed therapies for other solid organ malignancies. Poly (ADP‐ribose) polymerase inhibitors (PARPi... 
lysine‐specific histone demethylase‐1A | poly (ADP‐ribose) polymerase inhibitor | immune checkpoint inhibitor | cancer stem cell | triple‐negative breast cancer | triple-negative breast cancer | lysine-specific histone demethylase-1A | poly (ADP-ribose) polymerase inhibitor | PLACEBO | PD-L1 EXPRESSION | OVARIAN-CANCER | CANCER STEM-CELLS | PARP INHIBITOR | DNA-DEMETHYLATING AGENTS | THERAPY | ONCOLOGY | METASTATIC BREAST-CANCER | DOUBLE-BLIND | RESISTANCE | Homologous Recombination - drug effects | Neoplastic Stem Cells - drug effects | Humans | Clinical Trials as Topic | Triple Negative Breast Neoplasms - drug therapy | B7-H1 Antigen - genetics | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Up-Regulation - drug effects | Triple Negative Breast Neoplasms - genetics | Neoplastic Stem Cells - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Triple Negative Breast Neoplasms - metabolism | Immunotherapy | Female | Histone Deacetylase Inhibitors - pharmacology | Epigenesis, Genetic - drug effects | Histone Deacetylase Inhibitors - therapeutic use | Gene Expression Regulation, Neoplastic - drug effects | Drug Resistance, Neoplasm - drug effects | Epigenetic inheritance | Lysine | Cell death | Stem cells | Sugars | Monosaccharides | Drugs | Histone deacetylase | Transcription factors | DNA damage | Homologous recombination | Cytotoxicity | Cancer therapies | DNA repair | Immunosuppressive agents | Ovarian cancer | Proteins | Epidermal growth factor | Antitumor agents | Ribose | Cell cycle | Deoxyribonucleic acid--DNA | Phenotypes | Breast cancer | Chemotherapy | Immunogenicity | Response rates | Epigenetics | Ligands | Tumors | Apoptosis | Review
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 0027-8424, 2019, Volume 116, Issue 29, pp. 201908547 - 14582
...) growth and progression. Understanding the factors influencing AR-mediated gene expression provides new opportunities for therapeutic intervention. Poly(ADP-ribose) Polymerase (PARP... 
FOXA1 | prostate cancer | androgen receptor | ROLES | MULTIDISCIPLINARY SCIENCES | PARP inhibitor | PARP-2 | CELL-CYCLE | INCREASED SURVIVAL | DNA-REPAIR | EXPRESSION | POLY(ADP-RIBOSE) POLYMERASE-2 PARP-2 | Tissue Array Analysis | Humans | Receptors, Androgen - metabolism | Male | Hepatocyte Nuclear Factor 3-alpha - antagonists & inhibitors | Prostatic Neoplasms, Castration-Resistant - genetics | Prostatic Neoplasms, Castration-Resistant - pathology | Prostate - pathology | Gene Expression Regulation, Neoplastic - drug effects | Benzimidazoles - therapeutic use | Datasets as Topic | Kaplan-Meier Estimate | Poly (ADP-Ribose) Polymerase-1 - metabolism | Piperazines - therapeutic use | Signal Transduction - genetics | Prostatic Neoplasms, Castration-Resistant - drug therapy | Gene Knockout Techniques | Piperazines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Xenograft Model Antitumor Assays | Disease-Free Survival | Phthalazines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Phthalazines - therapeutic use | Poly(ADP-ribose) Polymerases - metabolism | Animals | Poly(ADP-ribose) Polymerases - genetics | Signal Transduction - drug effects | RNA-Seq | Cell Line, Tumor | Benzimidazoles - pharmacology | Mice | Prostatic Neoplasms, Castration-Resistant - mortality | Poly (ADP-Ribose) Polymerase-1 - genetics | RNA, Small Interfering - metabolism | DNA damage | Homologous recombination | Poly(ADP-ribose) | Homology | Genomes | Catalytic activity | Lethality | DNA repair | Critical components | Proteins | Castration | Ribose | Catalysis | Inhibition | Repair | Deoxyribonucleic acid--DNA | Poly(ADP-ribose) polymerase | Adenosine diphosphate | Pharmacology | Gene expression | Chemical compounds | Augmented reality | Poly(ADP-ribose) Polymerase 1 | Androgens | Antiandrogens | Ligands | Disruption | Prostate cancer | Prostate | Tumors | Cancer | Biological Sciences | PNAS Plus
Journal Article